安科生物：PA3-17注射液纳入拟突破性治疗品种

Core Viewpoint - Anke Bio (300009) announced that its associate company, Boshengji Pharmaceutical, has developed the PA3-17 injection, which has been included in the list of proposed breakthrough therapies by the National Medical Products Administration (NMPA) [1] Group 1 - The PA3-17 injection is intended for the treatment of adult relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/RT-ALL/LBL) [1]